Company ProfileGENY COMMERCIALISES ANTIBODY TECHNOLOGIES UNDER LICENSE FROM NATIONAL UNIVERSITY OF SINGAPORE. Our platform technology employs a powerful, trade secreted method to screen human memory B cells from the blood of convalescent patients. Using a blend of bioinformatics, massive parallel sequencing and high throughput functional assays, we identify fully human monoclonal antibodies responsible for having resolved the infection.This platform has spawned a pipeline of antibodies with proof of concept for the treatment and diagnosis of a range of infectious diseases, HBV, TB, dengue. GENY's lead therapeutic candidates are four promising monoclonal antibodies each specific against the four serotypes of dengue (DENV1-4), the most advanced is antibody 14C10 (anti-DENV1), which in pre-clinical testing has demonstrated rapid and enduring elimination of viral load in mouse challenge studies, and the ability to block viral transmission in mosquito feeding experiments using the matrix of infected human blood.GENY REDUCES INVESTOR RISK BY CO-DEVELOPING LOWER RISK, FASTER TO MARKET DIAGNOSTICS. Its lead diagnostic prototype is a rapid immunoassay for serotype-specific detection of dengue virus infection in human blood, that can specifically and sensitively differentiate dengue from zika virus and other flavivirus infections. Important in geographical regions where other flaviviruses co-exist. This is a game-changing differentiating characteristic, especially for Singapore, which is currently experiencing an outbreak of zika virus infections against a backdrop of endemic dengue infections.GENY IS GENERATING REVENUES having already brought to market its first immunoassay for detection of immunity to viral variants of SARS-CoV-2. This was registered for sale in the European Union and generated $0.5M in its first year at market.